Melanoma – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032

 Melanoma arises from the melanocytes of cutaneous or other pigmented tissues such as the eyes or intestines. About 90% of melanomas are diagnosed as primary tumors without any evidence of metastasis. Melanoma when malignant, has a marked propensity to metastasize to the brain. Australia has the highest melanoma incidence rate, and New Zealand has the highest melanoma mortality rate. The major oncogenic mutations associated with melanoma are BRAF, NRAS, c-KIT, PTEN and GNAQ/GNA11. BRAF is the most widely studied mutation; prevalence in primary melanoma ranges from 50% to 60%. Around 5% to 12% of the patients with melanoma have a family history of CMM in one or more first-degree relatives.

·       So far, more than 75 somatic mutations in the BRAF gene have been identified in melanoma, and all mutations at V600 in exon 15 constitutively activate BRAF.

·       The mutations are either in the activating segment in exon 15 or the glycine-rich loop (P-loop) in exon 11 of the kinase domain of the BRAF protein. In BRAF mutant melanoma, 74% to 90% are V600E, and 16% to 29% are V600K mutations. The frequency of BRAF mutation in primary melanomas ranges from 50% to 60%.

Thelansis’s “Melanoma Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Melanoma treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

KOLs insights of Melanoma across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Melanoma Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.

Read more: Melanoma – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032